文献速递分子诊断质量管理与危急值

SARS-CoV-2 NAAT工作流实验室内部优化的临床决策支持回顾性评价

Retrospective evaluation of clinical decision support for within-laboratory optimization of SARS-CoV-2 NAAT workflow.
PubMed 文献 · J Clin Microbiol · 2023-12-22

该研究回顾性分析了2020年3月至2022年6月共1,385,813例SARS-CoV-2 NAAT,评估基于医嘱录入时提问(AOE)生成标签图标以进行实验室内部标本分流的临床决策支持(CDS)工作流。多数检测达到机构委员会设定的周转时间(TAT)目标,但在高需求和供应短缺期间出现偏差;不同临床场景的TAT存在显著差异。

要点

  • 基于AOE问题生成标签图标的CDS工具可用于实验室内部标本分流。
  • 多数SARS-CoV-2 NAAT达到机构设定的TAT目标,高需求期出现偏差。
  • 不同标签图标标识的门诊场景间TAT存在显著差异。

核心结论

  • 基于AOE问题生成标签图标的CDS方法可帮助实验室对SARS-CoV-2 NAAT标本进行分流和优先处理。

研究设计与样本

  • 回顾性研究,纳入2020年3月至2022年6月共1,385,813例SARS-CoV-2 NAAT,评估基于AOE问题生成标签图标的CDS工作流。

主要发现

  • 多数检测达到机构委员会设定的TAT目标,但在高需求和供应短缺期间出现TAT偏差。
  • 急诊和住院标本及门诊术前人群的中位TAT在疫情期间保持稳定。
  • 医护人员及其他门诊检测的TAT随检测量和社区传播率大幅变化。
  • 急诊和住院临床场景的中位TAT在整个疫情期间存在显著差异。
  • 标签图标标识的门诊临床场景间TAT存在显著差异。

临床怎么用

  • 可使用基于AOE问题生成标签图标的CDS工具在实验室内对SARS-CoV-2 NAAT标本进行分流和优先处理。

局限性

  • 需进一步研究评估该CDS工具对整体实验室效率和患者结局的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The unprecedented demand for severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) testing led to challenges in prioritizing and processing specimens efficiently. We describe and evaluate a novel workflow using provider- and patient-facing ask at order entry (AOE) questions to generate distinctive icons on specimen labels for within-laboratory clinical decision support (CDS) for specimen triaging. A multidisciplinary committee established target turnaround times (TATs) for SARS-CoV-2 nucleic acid amplification test (NAAT) based on common clinical scenarios. A set of AOE questions was used to collect relevant clinical information that prompted icon generation for triaging SARS-CoV-2 NAAT specimens. We assessed the collect-to-verify TATs among relevant clinical scenarios. Our study included a total of 1,385,813 SARS-CoV-2 NAAT conducted from March 2020 to June 2022. Most testing met the TAT targets established by institutional committees, but deviations from target TATs occurred during periods of high demand and supply shortages. Median TATs for emergency department (ED) and inpatient specimens and ambulatory pre-procedure populations were stable over the pandemic. However, healthcare worker and other ambulatory test TATs varied substantially, depending on testing volume and community transmission rates. Median TAT significantly differed throughout the pandemic for ED and inpatient clinical scenarios, and there were significant differences in TAT among label icon-signified ambulatory clinical scenarios. We describe a novel approach to CDS for triaging specimens within the laboratory. The use of CDS tools could help clinical laboratories prioritize and process specimens efficiently, especially during times of high demand. Further studies are needed to evaluate the impact of our CDS tool on overall laboratory efficiency and patient outcomes. IMPORTANCE We describe a novel approach to clinical decision support (CDS) for triaging specimens within the clinical laboratory for severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) nucleic acid amplification tests (NAAT). The use of our CDS tool could help clinical laboratories prioritize and process specimens efficiently, especially during times of high demand. There were significant differences in the turnaround time for specimens differentiated by icons on specimen labels. Further studies are needed to evaluate the impact of our CDS tool on overall laboratory efficiency and patient outcomes.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Durant TJS, Peaper DR. Retrospective evaluation of clinical decision support for within-laboratory optimization of SARS-CoV-2 NAAT workflow. J Clin Microbiol. 2023. PMID: 38132702. doi:10.1128/jcm.00785-23

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。